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ABSTRACT

ARTICLE HISTORY

The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed
during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that
transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased in metastatic
castrate-resistant androgen receptor-negative prostate tumors compared to androgen receptor-positive
prostate tumors. In addition, the αVβ6 integrin protein levels are significantly elevated in androgen
receptor-negative PrCa patient derived xenografts (PDXs) compared to androgen receptor-positive
PDXs. In vitro, the androgen receptor-negative PrCa cells express high levels of the αVβ6 integrin
compared to androgen receptor-positive PrCa cells. Additionally, expression of androgen receptor (wild
type or variant 7) in androgen receptor-negative PrCa cells downregulates the expression of the β6 but
not αV subunit compared to control cells. We demonstrate an efficient strategy to therapeutically target
the αVβ6 integrin during PrCa progression by using short interfering RNA (siRNA) loaded into PrCa cellderived small extracellular vesicles (sEVs). We first demonstrate that fluorescently-labeled siRNAs can be
efficiently loaded into PrCa cell-derived sEVs by electroporation. By confocal microscopy, we show
efficient internalization of these siRNA-loaded sEVs into PrCa cells. We show that sEV-mediated delivery
of ITGB6-targeting siRNAs into PC3 cells specifically downregulates expression of the β6 subunit.
Furthermore, treatment with sEVs encapsulating ITGB6 siRNA significantly reduces cell adhesion and
migration of PrCa cells on an αVβ6-specific substrate, LAP-TGFβ1. Our results demonstrate an approach
for specific targeting of the αVβ6 integrin in PrCa cells using sEVs encapsulating ITGB6-specific siRNAs.
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Introduction
Prostate cancer (PrCa) is currently the second leading cause of
estimated cancer-related death in men in the US.1 Patients
with metastatic PrCa disease exhibit much less favorable out
comes with a 5-year survival rate of 30%.2 The development of
resistance to current therapeutic modalities in most advanced
lethal PrCa patients underscores the need for novel therapeu
tic targets and strategies.3,4 Furthermore, developing perso
nalized treatment methods for PrCa patients necessitates
understanding the expression pattern of differentially regu
lated genes and proteins in prostate tumor and their impact
on prostate tumor biology. Therapeutic targeting in PrCa
could then be directed against molecules that are overex
pressed in transformed cells relative to healthy tissue. One
such potential target is the epithelial-specific αVβ6 integrin.5–
7
The physiologic expression of the αVβ6 integrin is restricted
to development and epithelial re-modeling during tissue
repair.5 In contrast, its expression is upregulated in organ
fibrosis8–12 and solid tumors derived from breast, lung, liver,
stomach, pancreas, colon, cervix, and ovary, where it is gen
erally associated with poorer prognosis.13–20 The αVβ6
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integrin activates latent transforming growth factor beta 1
(TGFβ1), promotes epithelial-to-mesenchymal transition,
cellular migration, and matrix metalloproteinase activity in
cancer.13,15,21,22 In light of these attributes, the αVβ6 integrin
has been targeted for the treatment of different cancers using
diverse strategies.18,19 Our group has demonstrated that
expression of the αVβ6 integrin is not detectable in normal
human prostate; however, it is highly expressed in human
primary PrCa,23 PrCa bone metastases,24 and peripheral
blood mononuclear cells (PBMC) from PrCa patients.7 The
αVβ6 integrin expression plays an important role in prostate
tumor progression by promoting colony formation,25 cell
adhesion, cell migration on an αVβ6-specific substrate, the
latency-associated peptide (LAP)-TGFβ,26 as well as activa
tion of an osteolytic program by inducing matrix degradation
through MMP2.24 Furthermore, PrCa cell-derived small
extracellular vesicles (sEVs) play an important role in prostate
tumor microenvironment;27,28 transfer of αVβ6 integrin via
PrCa cell-derived sEVs results in increased migration of reci
pient PrCa cells,6 M2 polarization of monocytes,7 and
angiogenesis.29
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To investigate the potential therapeutic utility ofαVβ6 integ
rin targeting in PrCa, our group has previously established that
treatment of Ptenpc-/ – mice containing a prostate-specific
deletion of the Pten tumor suppressor with 6.3G9, an antiαVβ6 non-ligand-mimetic blocking monoclonal antibody that
is not internalized upon binding,30 results in a significant
decrease in prostate tumor weight.23 Despite the rapid progress
made toward the development of potent anti-cancer therapeu
tic antibodies, challenges remain to overcome their limitations,
including side effects, immunogenicity, low efficacy due to
resistance to therapy, access to targets, the complexity of bio
logical systems, and individual variations.31 Therefore, tissuespecific, nontoxic, and non-immunogenic delivery technolo
gies are critical to move therapeutic modalities into clinical
practice for cancer therapy. In this context, recent reports have
shown the therapeutic utility of exosomes.32–35 Exosomes are
sEVs of endosomal origin that are released from all cells.27,33,36
The current sEV isolation protocols typically purify a mixture
of endosomal (namely, exosomes) and non-endosomal sEVs.37
Therefore, for the purposes of this study, sEVs are defined as
a
population
of
EVs
recovered
by
100,000
xg ultracentrifugation followed by iodixanol density gradient
isolation, <200 nm in size, endosomal or non-endosomal in
origin, and secreted by fusion with the plasma membrane.36–38
sEVs carry RNA, DNA, and proteins from their cells of origin,
are captured and internalized by recipient cells, and can mod
ulate recipient cell phenotypes by delivering their cargo.27,28
sEVs can be engineered to deliver short interfering RNAs
(siRNAs), antisense oligonucleotides, antibodies, or che
motherapeutic drugs to a desired target.33,39 It has been
reported that delivery of sEVs loaded with siRNAs to target
cancer tissues/cells can accomplish specific gene knockdown
and inhibit tumor growth in mouse models.34,35,40
Based on these previous findings, we hypothesize that inhi
bition of the β6 subunit expression in PrCa cells through sEVmediated delivery of siRNAs against ITGB6 might conse
quently impact the functions of the αVβ6 integrin in PrCa
cells. Here, we demonstrate an efficient strategy to therapeuti
cally target the αVβ6 integrin during PrCa progression by
using siRNAs loaded into PrCa cell-derived sEVs. Upon inter
nalization, these sEVs deliver ITGB6-targeting siRNAs to reci
pient PrCa cells, thereby inhibiting expression of the β6
subunit and significantly reducing cell adhesion and migration
of the cells on the αVβ6 integrin specific substrate, LAPTGFβ1. Taken together, our results support the feasibility of
using sEVs bearing ITGB6 siRNA to directly modulate expres
sion of the αVβ6 integrin as a potential therapeutic strategy for
PrCa.

Results
αVβ6 integrin expression negatively correlates with
androgen receptor levels in prostate cancer.
Our group has previously reported that expression of the
αVβ6 integrin in the LNCaP PrCa cell line causes an
increase in androgen receptor (AR) activity without indu
cing changes in AR proteins’ endogenous expression.23
However, inversely, the impact of AR expression on the

αVβ6 integrin expression has never been explored. To
address this issue, we first interrogated the RNAsequencing dataset41 on metastatic castrate-resistant pros
tate cancer (mCRPrCa) specimens and classified them
according to their presence or absence of AR expression.
Our analysis shows a significantly increased expression of
the ITGB6 transcript, which encodes the β6 integrin sub
unit, in AR-negative tumors (n = 19, P = 10,−8 MannWhitney test) compared to AR-positive tumors (n = 89)
(Figure 1a). To corroborate these findings from RNAsequencing data, we classified the LuCaP patient-derived
xenografts (PDXs)41,42 based on presence or absence of
AR expression, and compared their αVβ6 integrin expres
sion levels as determined by immunohistochemistry (IHC),
previously published by our group.43 Our data demonstrate
a significantly increased expression of the αVβ6 integrin in
AR-negative LuCaP PDXs (n = 6, P = .005, Mann-Whitney
test) compared to AR-positive PDXs (n = 36) (Figure 1b).
Moreover, the analysis of the mRNA dataset from the
Prostate Cancer Transcriptome Atlas (PCTA) web tool44
shows a significant negative correlation between mRNA
expression of ITGB6 and AR in mCRPrCa cases
(r = −0.328, P = 6x10,−8 Spearman correlation).
Additionally, immunoblotting (IB) analysis reveals that the
β6 subunit is not expressed in AR-positive cell lines (C42B, LNCaP), whereas it is highly expressed in AR-negative
PrCa cell lines (PC3 and NCI-H660) (Figure 1d).
Furthermore, the DU145 PrCa cell line does not express
either AR or the β6 subunit. Our IB data also demonstrate
that the αV subunit is expressed in all PrCa cells analyzed,
irrespective of their AR expression status (Figure 1d). The
AR splice variant 7 (AR-V7), has emerged as a biomarker
for mCRPrCa.45 Therefore, we next investigated the β6
subunit levels upon transient expression of AR-V7 in PC3
cells compared to control AR-V7 negative PC3 cells. By IB
analysis, our data demonstrate a reduction in the expres
sion of β6 subunit in PC3 cells that transiently express ARV7 (Figure 1e) or full-length AR (AR-WT; Figure 1f)but
not αV subunit compared to control AR-negative PC3 cells.
Overall, our data are consistent with a central role for AR
loss on αVβ6 integrin expression during PrCa progression.
Small extracellular vesicles loaded with fluorescentlylabeled siRNAs are efficiently internalized into prostate
cancer cells.
Since αVβ6 integrin is highly expressed during progression
of PrCa,23,24 we explored the therapeutic utility of ITGB6
siRNA-loaded small extracellular vesicles (sEVs) on PrCa
cells. For exogenous loading of siRNAs, sEVs were isolated
from serum-starved conditioned media from PrCa cells
(DU145 and PC3) by high-speed differential ultracentrifu
gation (100,000 xg). To further remove protein and nonvesicular contaminants, we performed density gradient iso
lation of sEVs.29 The DU145 cell-derived sEVs were floated
on an iodixanol density gradient and sEVs in fractions one
to ten were characterized by IB. Our IB analysis shows that
β6 subunit expression is observed only in PC3 TCL whereas
it is absent in DU145 TCL; the sEV markers ALIX,
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Figure 1. αVβ6 integrin expression and its correlation with androgen receptor in prostate cancer. (a) RNAsequencing analysis of metastatic castrate-resistant prostate
cancer (mCRPrCa) specimens acquired through rapid autopsy.41 Specimens are classified based on their levels of androgen receptor (AR). The bar graphs show ITGB6
expression as Log base 2 fragments per kilobase of transcript per million mapped reads (FPKM) in AR-positive (AR+, n = 89) and AR-negative (AR-, n = 19) cases. The values
are presented as mean ± SEM; P values were calculated by the Mann-Whitney non-parametric test. (b) Analysis of the immunohistochemical (IHC) results of αVβ6 integrin
expression in 42 LuCaP PDX models42,43 classified based on expression of AR. Bar graphs show the Log base 2 (1+ IHC score) for αVβ6 integrin expression in AR+ (N = 36) and
AR – (N = 6) LuCaP PDXs. The values are presented as mean ± SEM; P values were calculated by using the Mann-Whitney non-parametric test. (c) Correlation between ITGB6
and AR expression in mCRPrCa cases acquired using the Prostate Cancer Transcriptome Atlas web tool.44 The scatter plot with linear regression line represents the
normalized AR expression values on the ordinate and, on the abscissa, the normalized ITGB6 expression values in mCRPrCa cases. P-values were calculated using the
correlation test R function. (d) IB analysis for expression of AR, β6 subunit, ACTIN as loading control (reducing conditions), and αV, ACTIN as loading control (non-reducing
conditions) in total cell lysates (TCL) from C4-2B, LNCaP, DU145, PC3, and NCI-H660 PrCa cells. (e) IB analysis (reducing conditions) for expression of AR-V7, β6 subunit and
ACTIN as loading control in total cell lysates from PC3 parental cells, PC3 cells treated with lipofectamine, transiently transfected with pEGFP-C3 empty vector, or the pEGFPC1-AR-V7 vector. (f) IB analysis for expression of AR, β6 subunit and ACTIN as loading control (reducing conditions) and αV subunit, TSG101 as loading control (non-reducing
conditions) in total cell lysates from PC3 cells transiently transfected with pEGFP-C3 empty vector or pEGFP-C1-AR-WT vector.

TSG101, CD9 are expressed in iodixanol density gradient
isolated fractions, whereas β6 subunit expression is absent
in all iodixanol density gradient isolated, DU145-derived,
sEV fractions (Figure 2a). We then pooled the sEVs floating
in fractions one to five (F1-F5) corresponding to density
1.077–1.151 g/mL and characterized by nanoparticle track
ing analysis (NTA). The NTA data from PC3 and DU145
sEVs (F1-F5) show that the majority of the sEVs exhibit a
particle size of <150 nm (Figure 2b). The pooled iodixanol
density gradient purified sEVs were further characterized by
IB for expression of the β6 subunit and sEV markers. Our
IB analysis on TCL and sEVs (F1-F5) from PC3 and DU145
cells shows expression of the β6 subunit only in PC3 TCL
and sEVs. The sEV markers CD63, CD81, ALIX, TSG101
and CD9 are expressed in sEVs (F1-F5) (Figure 2c) whereas

the endoplasmic reticulum marker calnexin (CANX) is only
expressed in TCL but not in sEVs derived from both PC3
and DU145 cells.
With the objective to utilize sEVs for delivery of siRNAs
into PrCa cells, we adapted an experimental protocol published
previously,34 and optimized it to electroporate DU145 and PC3
sEVs with siRNAs (Figure 3a). To visualize the sEV-mediated
delivery of siRNAs into PrCa cells, we utilized fluorescentlylabeled Cy®3 DsiRNAs for loading into sEVs. , Since electro
poration can cause aggregation and voltage-mediated damage
of EVs46,47 , we first investigated whether electroporationmediated loading of DU145 and PC3 sEVs with Cy®3
DsiRNAs impact the size of sEVs. Our NTA data show that
the majority of the DU145 or PC3 sEVs pre- (data not shown)
or post-electroporation without or with Cy®3labeled DsiRNAs
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Figure 2. Characterization of prostate cancer cell-derived small Extracellular Vesicles (sEVs). (a) IB analysis (reducing conditions) for expression of β6 subunit,
ALIX, TSG101, CD9, in PC3 total cell lysate, DU145 total cell lysate (TCL) and lysates from density gradient-isolated DU145 small extracellular vesicles (sEVs) in fractions
one to ten. (b) Nanoparticle tracking analysis (NTA) of the PC3 and DU145 cell-derived, density gradient-isolated sEVs pooled from fractions one to five (sEV F1-F5). (c) IB
analysis for expression of CD63, CD81, CANX (non-reducing conditions), and β6 subunit, ALIX, TSG101, CD9 (reducing conditions) in PC3 TCL, PC3 sEVs (F1-F5), DU145
TCL and DU145 sEVs (F1-F5).

exhibit a comparable particle size of <150 nm (Figure 3b). To
investigate the efficiency of Cy®3 DsiRNA loading into DU145
and PC3 sEVs, we measured the fluorescence of Cy®3 DsiRNAs
encapsulated within sEVs with excitation at 520 nm and emis
sion at 580–640 nm. A high Cy®3 fluorescence from DU145
and PC3 sEVs loaded with Cy®3 DsiRNAs is detected com
pared to DU145 and PC3 sEVs loaded without Cy®3 DsiRNAs
(Figure 3c). We further investigated whether DU145 and PC3
sEVs encapsulating Cy®3 DsiRNAs are efficiently internalized
into the PrCa cells. For this experiment, we incubated PC3
recipient cells with DU145-derived sEVs loaded with Cy®3
DsiRNAs, and DU145 recipient cells with PC3-derived sEVs
loaded with Cy®3 DsiRNAs, and performed confocal micro
scopy. Z-stack analysis of confocal microscopy images reveals
that Cy®3 DsiRNAs-loaded DU145 and PC3 sEVs are interna
lized and colocalize with endogenous actin in PC3 (28.7%) and
DU145 (27.4%) recipient cells (Figure 3d).

Small extracellular vesicle-mediated transfer of ITGB6targeting siRNAs to prostate cancer cells inhibit adhesion
and migration on LAP-TGFβ1.
We hypothesize that sEV-mediated delivery of ITGB6-tar
geting siRNAs into αVβ6 integrin expressing PC3 cells
might inhibit expression of the αVβ6 integrin and confer
an integrin loss-of-function phenotype. Our group has pre
viously shown that the β6 subunit is expressed in PrCa cellderived sEVs and efficiently transferred, via these sEVs, to
other prostate cells.6 Therefore, to avoid the possibility of
sEV-mediated transfer of β6 subunit to recipient cells, we
utilized DU145 sEVs (which do not express the β6 subunit)
for electroporation-mediated loading with ITGB6-targeting

siRNAs. Our NTA data reveal comparable sizes of DU145
sEVs electroporated without siRNAs, with non-silencing
siRNAs (+siNS sEVs), or with D1, an ITGB6-targeting
siRNA (+siITGB6 sEVs) (Figure 4a). IB analysis shows a
reduction in expression of the β6 subunit but no change in
expression of the β5 subunit, which is also known to
associate with the αV integrin subunit, in TCL from PC3
cells treated with +siITGB6 sEVs compared to PC3 parental
cells (-), PC3 cells treated with sEVs electroporated without
siRNAs (+), or +siNS sEVs (Figure 4b). In a separate
experiment, we also tested a different human ITGB6-target
ing siRNA (D13.1). D13.1 siRNA effectively downregulates
β6 subunit only upon oligofectamine-mediated transfection
of PC3 cells (Supplementary Figure 1a) but not without
oligofectamine (Supplementary Figure 1b). Treatment of
PC3 cells with DU145-derived sEVs loaded with D13.1
effectively reduces expression of β6 compared to PC3 par
ental cells (-), PC3 cells treated with sEVs electroporated
without siRNAs (+), or +siNS sEVs (Supplementary
Figure 1c).
We next investigated whether inhibition of the β6 subunit in
PC3 cells by +siITGB6 sEVs might affect the ability of PC3 cells to
adhere and migrate on extracellular matrix proteins such as fibro
nectin (FN) and LAP-TGFβ1, two major ligands found in the
tumor microenvironment and specific for the αVβ6 integrin.9,48
We find that upon inhibition of the β6 subunit by +siITGB6 sEVs,
there is no significant change in PC3 cell adhesion and migration
on FN (Figure 4c, d) compared to PC3 cells that were treated with
+siNS sEVs. In contrast, inhibition of the β6 subunit due to
+siITGB6 sEVs significantly abrogates adhesion of PC3 cells on
LAP-TGFβ1 compared to PC3 cells that were treated with +siNS
sEVs (P = .037, Figure 4c). Furthermore, treatment with +siITGB6
sEVs of PC3 cells that do adhere under longer incubation
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Figure 3. Small Extracellular Vesicle (sEV)-mediated delivery of Cy®3 DsiRNAs to prostate cancer cells. (a) Schematic representation of the experimental approach
for siRNA electroporation into sEVs followed by different analyses. (b) The upper panel shows NTA of the DU145 sEVs electroporated without DsiRNAs or DU145 sEVs
electroporated with Cy®3 DsiRNAs. The bottom panel shows NTA of PC3 sEVs electroporated without DsiRNAs or PC3 sEVs electroporated with Cy®3 DsiRNAs. (c)
Fluorescence intensity from DU145 sEVs electroporated without DsiRNAs (EP) or DU145 sEVs electroporated with Cy®3 DsiRNAs (top panel) and PC3 sEVs electroporated
without DsiRNAs (EP) or PC3 sEVs electroporated with Cy®3 DsiRNAs (bottom panel). Bar graphs show fluorescence measured as Optical Density (O.D.) in arbitrary units
(a.u.) at 580–640 nm. Values are presented as mean ± SEM. (d) Confocal microscopy analysis was carried out to evaluate internalization of sEVs loaded with Cy®3
DsiRNAs into PrCa cells. Left, Z-stack analysis showing DU145-derived sEV-mediated internalization of Cy®3 DsiRNAs into PC3 recipient cells. Right, Z-stack analysis
showing PC3-derived sEV-mediated internalization of Cy®3 DsiRNAs into DU145 recipient cells. Cy®3 DsiRNA emits Orange fluorescent signal, FITC Phalloidin was used to
label actin (green) and DAPI was used to detect nuclei (blue). Left, scale bar = 33 µm; right, scale bar = 11 µm.

conditions on LAP-TGFβ1-coated Transwell inserts (Figure 4d,
left panel) shows no effect on cell attachment, but a significant
reduction in migration on LAP-TGFβ1 compared to parental cells
(-) (P < .0001) as well as PC3 cells treated with sEVs electroporated
without siRNAs (+) (P = .0004) or +siNS sEVs (P = .0006) (Figure
4d, right& bottom panel). Overall, our data indicate that DU145derived sEV-mediated delivery of ITGB6-targeting siRNAs into
PC3 recipient cells not only efficiently downregulates expression of
the β6 subunit in these cells, but also confers as scratchedadhesive
and migratory phenotypes that closely resemble those caused by
the loss of αVβ6 integrin functions (Figure 5).

Discussion
Here, we show for the first time that expression of the
ITGB6 transcript and expression of the αVβ6 integrin pro
tein have a significant negative correlation with AR

expression in mCRPrCa patient tumors and LuCaP PrCa
PDX models, respectively. Expression of AR in an ARdeficient cell line results in downregulation of the β6 integ
rin subunit. Furthermore, by sEV-mediated delivery of
ITGB6-targeting siRNAs into PrCa cells, we demonstrate a
significant abrogation of the β6 subunit expression and
consequent inhibition of adhesive and migratory potential
of the recipient PrCa cells. Overall, our data suggest that
sEV-mediated delivery of ITGB6-targeting siRNAs could
serve as a potential therapeutic modality against the αVβ6
integrin-positive PrCa tumors.
According to published reports, the expression pattern of
the αVβ6 integrin is highly heterogeneous in primary prostate
tumors; it is highly expressed in bone metastatic PrCa cases,
whereas its expression is undetectable in neuroendocrine PrCa
(NEPrCa) cases and normal prostatic epithelium.23,24,43
However, none of these studies examined the correlation
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Figure 4. In vitro efficacy of small Extracellular Vesicles (sEVs) loaded with siRNAs targeting ITGB6. (a) NTA of the density gradient-isolated DU145 sEVs
electroporated without siRNAs (left), electroporated with non-silencing siRNAs (+siNS, middle), or electroporated with siRNAs targeting ITGB6 (+siITGB6, right). (b) IB
analysis of TCL from PC3 parental cells (-), PC3 cells treated with DU145 sEVs electroporated without siRNAs (+), +siNS sEVs, or +siITGB6 sEVs for expression of β6
subunit, β5 subunit, and ACTIN as loading control. (c) PC3 cells treated with +siNS, or +si DU145 sEVs were seeded (2.5x104, 3 replicates) for 2.5 hours on BSA (1%),
fibronectin (FN, 10 µg/mL), or LAP-TGFβ1 (10 µg/mL)-coated wells. The bar graphs represent the degree of cell adhesion quantified as O.D. of crystal violet staining
measured at 562 nm. The values are presented as mean ± SEM; P values were calculated by the two-group t-test with Welch’s correction. (d) The PC3 parental cells (-),
PC3 cells treated with DU145 sEVs electroporated without siRNAs (+), +siNS sEVs, or +siITGB6 sEVs were plated (5x104, 3 replicates) on BSA (1%), FN (10 µg/ml), LAPTGFβ1 (7 µg/mL)-coated Transwell chambers in serum-free media in the top and bottom chambers. The bar graphs in the left panel represent the adhered PC3 cells/
field of view (FOV) in 6 hours on BSA, FN, or LAP-TGFβ1 in each treatment group (15 fields for each condition; FOV = 0.044 mm diameter). The bar graphs in the right
panel represent the percentage of PC3 cells migrated in 6 hours on BSA, FN, or LAP-TGFβ1 toward the bottom chambers in each treatment group (24 fields for each
condition; FOV = 0.044 mm diameter). The values are reported as mean ± SEM; The P values were calculated by ANOVA with post-hoc Holm-Sidak’s multiple
comparisons test for migration on BSA and FN, and the Kruskal-Wallis test with post-hoc Dunn’s multiple comparisons test for migration on LAP-TGFβ1. The lower
panels show representative images of PC3 cells migrated on LAP-TGFβ1 toward the bottom of Transwell chambers upon treatment with DU145 sEVs electroporated
without siRNAs (+), +siNS sEVs, or +siITGB6 sEVs.

between the αVβ6 integrin and AR expression in PrCa patients.
In vitro, we show that the β6 subunit is not expressed in AR+
PrCa cells (C4-2B, LNCaP) whereas it is expressed in AR- PrCa
cells (PC3, NCI-H660). Notably, our data reveal that β6 expres
sion is absent in AR- DU145 cells; we speculate that this
observation could be attributed to DNA methylation, posttranscriptional silencing of ITGB6, or post-translational silen
cing of the αVβ6 integrin in DU145 cells. Taking into consid
eration our previous and current findings, we propose the
emergence of AR+, αVβ6- and AR-, αVβ6+ tumor subtypes
in addition to previously described AR+, αVβ6+ subtype dur
ing PrCa progression.23,41 Co-existence of these three subtypes
within the same prostate tumor could also be a possibility. Both
AR and the αVβ6 integrin are expressed in PrCa cell-derived
sEVs;6,49 and the sEV-mediated transfer of these molecules
between prostate tumor subtypes as well as its impact on
PrCa progression need further investigation. Thus, increased

expression of the αVβ6 integrin during PrCa progression and
its oncogenic manifestations,6,7,23,24,26,29 makes it an attractive
target for the αVβ6+ subsets in PrCa.
Previous attempts to target the αVβ6 integrin using
BG00011 antibody have raised issues related to safety and
efficacy.50 Additionally, the strategies to therapeutically target
the αVβ6 integrin in different cancers have not yet as scratch
eden successful.51 As an alternative strategy, significant interest
has emerged in utilizing sEVs as potential tumor-targeted
vehicles for cancer therapy. sEVs provide a relatively stable
environment for transport of the therapeutic agent of choice,
can be modified to improve cell-specific targeting, and have the
ability to enter the cells, thus allowing the therapeutic cargo to
be delivered.33,39,52,53 With regard to toxicity and immuno
genicity as main challenges of cell-based therapies, sEVs are
thought to be well tolerated and deliver cargo with minimal
immune clearance.33 Multiple studies have reported successful
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Figure 5. Proposed model for small Extracellular Vesicle (sEV)-mediated delivery of ITGB6 targeting siRNAs in AR-negative prostate cancer cells. The schematic
diagram shows that DU145 sEVs electroporated with ITGB6 siRNAs, upon internalization into PC3 cells, release the cargo into the cytoplasm out of the endosomal
compartment; this results in RISC-mediated silencing of ITGB6 mRNA and consequent reduced expression of the β6 subunit. This reduced expression of the β6 subunit in
turn leads to reduced adhesion and migration of PC3 cells on the αVβ6-specific ligand LAP-TGFβ1.

utilization of electroporation as a technique to load siRNAs
into sEVs and downregulate the expression of specific targets.
32,34,40,54
A few studies have also reported that electroporation
can induce aggregation and at high voltages cause damage of
EVs.46,47 Our NTA data show a comparable pre- and postelectroporation sEV sizes suggesting that electroporation of
siRNAs into sEVs does not cause aggregation or voltageinduced damage to sEVs in our system. Furthermore, to inves
tigate the internalization efficiency of sEVs encapsulating
siRNAs into the PrCa cells, we utilized fluorescently-labeled
Cy®3 DsiRNAs. Consistent with previous findings,32,55–58 we
observe an efficient internalization of sEVs loaded with Cy®3
DsiRNAs. Overall, our data suggest that electroporationmediated encapsulation of siRNAs into sEVs does not alter
sEV integrity or internalization efficacy.
Our data for the first time demonstrate that sEVs
encapsulating ITGB6-targeting siRNAs abrogate expression
of the β6 subunit in PrCa cells. In terms of specificity, no
change in the levels of the β5 subunit, which is also
known to associate with the αV integrin subunit, was
observed, thus indicating that there are no apparent offtarget effects of sEV-mediated ITGB6 siRNA delivery in
PrCa cells. It has been recently reported that within

recipient cells, the EVs are internalized in endo/lysosomal
compartments; the mechanisms associated with endo/lyso
somal escape of siRNA cargo remain unknown.59,60 The
efficient inhibition of the β6 subunit in PrCa cells indi
cates that upon sEV-mediated internalization, the ITGB6
siRNAs could bypass degradation by the endo/lysosomal
pathway. We observe a significantly reduced adhesion and
migration of PC3 cells treated with ITGB6 siRNA-loaded
sEVs on the αVβ6-specific substrate, LAP-TGFβ1.
However, we do not observe any significant impact on
adhesion or migration of these cells on fibronectin. This
result could be attributed to the involvement of another
fibronectin receptor such as the β1 integrin48 that is
abundantly expressed by these PrCa cells. In this study,
for ITGB6 siRNA delivery, we utilized sEVs derived from
DU145 PrCa cells that do not express the β6 subunit.
However, using PrCa cell-derived sEVs for preclinical
and clinical intervention of the αVβ6 integrin and conse
quent reduction in prostate tumor growth and metastases,
may pose challenges. In this context, it has been demon
strated that sEVs isolated from bone marrow-derived
mesenchymal stem cells (MSC-sEVs) are stable in circula
tion due to the presentation of CD47 on their surface.35
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Therefore, future in vitro and in vivo studies aiming at
inhibiting of the αVβ6 integrin in prostate tumors could
potentially be optimized by using MSC-sEVs.
Collectively, our results indicate that by employing
sEV-mediated delivery of siRNAs targeting the ITGB6
gene, the functional abrogation of the αVβ6 integrin
might be achieved in human PrCa cells. Further evalua
tion of this sEV-mediated targeting of prostate tumors in
preclinical and clinical models might ultimately lead to
the development of new therapeutic methods to prevent
and/or delay prostate cancer progression to advanced
stages.

Materials and methods
RNA-sequencing of mCRPrCa samples
RNA-sequencing analysis of mCRPrCa specimens acquired
through rapid autopsy was performed, as previously
described.41 Based on expression of the AR transcript, the
mCRPrCa specimens were classified as AR+ (n = 89) or AR(n = 19). ITGB6 Log2 Fragments Per Kilobase of transcript per
Million (FPKM) mapped reads in these AR+ and ARmCRPrCa specimens were compared, as described in the sta
tistical analysis section below.

H0135), 10 nM beta-estradiol (Sigma-Aldrich, E227), 5 mL of
L-glutamine (Gibco, 25030081), and PenStrep. The PC3 cells
were cultured in RPMI media supplemented with 10% FBS and
PenStrep.
Transient expression of AR-V7 and AR-WT
For transient expression of AR, PC3 cells were plated (2x105) in
a 6-well plate and grown overnight at 37°C. The following day,
the cells were washed with phosphate buffered saline (PBS) and
incubated with 1 mL serum-free medium at 37°C for 2 hours.
For transfection, 4 μg pEGFP-C3 empty vector, pEGFP-C1AR-V7 vector or pEGFP-C1-AR-WT vector were mixed with
12 μL of lipofectamine 2000 (Invitrogen, 11668–019) in 200 μL
of serum-free RPMI medium. The pEGFP-C3-lipofectamine,
pEFGP-C1-AR-V7-lipofectamine, or pEFGP-C1-AR-WTlipofectamine mix were incubated at room temperature for
25 minutes and added drop-wise to PC3 cells followed by
incubation at 37°C for 6 hours. After 6 hours, 700 μL of
complete medium (without PenStrep) were added to the cells
and incubated at 37°C, overnight. The following day, a second
round of transfection was performed as described above and
after overnight incubation at 37°C, the transfection medium
was replaced with complete medium and the cells were incu
bated at 37°C for 48 hours followed by preparation of TCL as
mentioned below.

LuCaP PDX tumor microarray (TMA) IHC assessment
The TMA containing 42 LuCaP PDX models were utilized for
the IHC staining of the αVβ6 integrin followed by generation
of an IHC score, as previously published.43 Based on their IHC
staining scores for AR expression, these 42 LuCaP PDXs were
classified as AR+ (n = 36) or AR – (n = 6). The IHC scores for
the αVβ6 integrin in AR+ and AR- LuCaP PDXs were com
pared, as described in the statistical analysis section below.
Prostate cancer transcriptome atlas (PCTA)
The transcriptome data of mCRPrCa cases (n = 260) were
downloaded from the PCTA web tool.44 The association
between transcript levels of ITGB6 and AR was analyzed as
described in the statistical analysis section below.
Cell lines
All PrCa cells (C4-2B, DU145, LNCaP, NCI-H660, PC3) were
purchased from ATCC, and cultured in a humidified atmo
sphere of 5% CO2 at 37°C using their respective medium. The
C4-2B and LNCaP cells were cultured in RPMI medium
(Corning, 10–040-CV) supplemented with 5% fetal bovine
serum [(FBS), Hyclone, SH30396.03], 1 mM sodium pyruvate
(Corning, 25–000-CI), 5 mL of MEM non-essential amino acids
(Corning, 25–025-CI), 50 U/mL penicillin and 50 μg/mL strep
tomycin [(PenStrep), Corning Cellgro, 30–001-CI)]. The
DU145 cells were cultured in DMEM medium (Corning, 10–
013-CV) supplemented with 10% FBS, and PenStrep. The NCIH660 cells were cultured in RPMI medium supplemented with
5% FBS, 5 mL of ITS liquid medium supplement (SigmaAldrich, 13146), 10 nM Hydrocortisone (Sigma-Aldrich,

siRNA transfection of PC3 PrCa cells
Using oligofectamine, PC3 parental cells were transiently
transfected with 100 nM of non-silencing (NS) siRNA (Cat.
No. D-001810-01-20; Dharmacon), human ITGB6 targeting
siRNA duplex D1 (sense: 5’-AGGACTCAACTTGUC
ATTTACAGCC-3’, antisense: 5’-GGCUGUAAAUGACAA
GUU-3’) or D13.1 (sense 5’ GUCACUUGGACAGCAAG
AAUGAATA-3’, antisense 3’-GACAGUGAACCUGUCGU
UCUUACUUAU-5’), as previously described.61 PC3 parental
cells were also treated with 100 nM of NS or D13.1 siRNAs
without oligofectamine. Briefly, 2x105 cells were plated in a 6well plate for 24 hours. Then, cells were serum starved and
100 nM of NS or D13.1 siRNA without oligofectamine were
added to the respective wells dropwise. Cells were incubated at
37°C for 8 hours. After 8 hours, complete medium was added
to the cells. The same process was repeated the following day.
After two rounds of siRNA treatment cells were lysed.
Immunoblotting (IB) analyses and antibodies
For IB, total cell lysates (TCL) or sEV lysates were prepared
using Radio Immuno Precipitation Assay (RIPA) buffer
(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1%
SDS, 1% Triton X-100, and 1% sodium deoxycholate) supple
mented with protease inhibitors (calpain, aprotinin, leupeptin,
pepstatin, sodium fluoride, sodium orthovanadate). The total
protein concentration of lysates was determined using DCTM
protein assay kit (Bio-Rad, 5000112) as per the manufacturer’s
protocol. Equal amounts of proteins in non-reducing (heated
without 2-Mercaptoethanol) and reducing conditions (heated
with 2-Mercaptoethanol) were separated by Sodium Dodecyl
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Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE),
transferred to polyvinylidene difluoride (PVDF) membranes
(Millipore, Immobilon-E PVDF membrane, pore size 0.45 µm,
IEVH00005), blocked with buffer (5% nonfat dry milk) in Tris
Buffer Saline with 0.1% Tween 20 (TBST) at room temperature
for 1 hour, incubated overnight with primary Abs at 4°C, as
described below, followed by TBST washes at room tempera
ture (4 x 10 minutes), incubation with horseradish peroxidase
(HRP)-conjugated anti-goat, -mouse or -rabbit secondary Abs
as described below for 1 hour at room temperature, followed by
TBST washes (4 x 10 minutes) at room temperature. For
visualization, WesternBrightTM ECL HRP substrate kit
(Advansta, K-12045-D50) was used.
The following primary antibodies (Abs) were used for IB
analyses: goat polyclonal Ab against the αVβ6 integrin (R&D
Systems, AF2389); mouse monoclonal Abs against: αVβ6
integrin (Biogen, 6.2A1), ALIX (Abcam, ab117600), AR
(Santa Cruz, sc-7305), CD9 (Santa Cruz, sc-13118), CD63
(Abcam, ab8219), CD81 (Abcam, ab23505); rabbit monoclonal
Abs against β5 integrin subunit (Cell Signaling, 3629), TSG101
(Abcam, ab125011); rabbit polyclonal Abs against: ACTIN
(Sigma Aldrich, A2066), Calnexin (CANX) (Cell Signaling,
2433S), and rabbit antiserum against αV subunit (C-terminus).
The following secondary Abs were used for IB analyses: HRPlinked anti-goat IgG (R&D Systems, HAF019), HRP-linked
anti-mouse IgG (Cell Signaling, 7076S) and HRP-linked antirabbit IgG (Cell Signaling, 7074S).
Small extracellular vesicle isolation
As published previously,62 for sEV isolation, PrCa cells (PC3
and DU145) were plated in 150 mm cell culture dishes
(ThermoScientific, 130183) in their respective complete med
ium, as described above. After 48 hours of incubation at 37°C,
cells were washed with PBS and incubated with serum-free
medium (complete media devoid of FBS) for the next
48 hours. The sEVs were isolated by high-speed differential
ultracentrifugation of the supernatant (SN) collected after
48 hours of serum-starvation. The dead cells and cell debris
were spun down from SN at 2000 xg, 4°C for 20 minutes. The
SN collected was spun at 10,000 xg, 4°C for 35 minutes. Next,
the SN collected without disturbing the 10,000 xg pellet was
spun at 100,000 xg, 4°C for 70 minutes; the pellet was washed in
40 mL PBS followed by a second spin at 100,000 xg, 4°C for
70 minutes. The 10,000 xg and 100,000 xg centrifugation were
done in a Beckman Type 45Ti rotor using a Beckman L8-70M
Ultracentrifuge. The final sEV pellets were resuspended in
100 μL PBS.
Small extracellular vesicle isolation by iodixanol density
gradient centrifugation
For iodixanol density gradient separation, the sEVs obtained
from PC3 or DU145 cells were suspended in 1.636 mL of 30%
iodixanol-buffer solution [made by mixing 1:1 of 60% (weight/
volume) stock solution of iodixanol (Sigma, OptiPrepTM,
D1556) with a stock buffer [(0.25 M sucrose, 10 mM Tris
(pH 8.0), 1 mM EDTA, pH 7.4)] and layered at the bottom
of an ultracentrifugation tube. Next, 0.709 mL of 20%
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iodixanol-buffer solution and 0.654 mL of 10% iodixanol-buf
fer solution were successively layered on top of the 30% iodix
anol-vesicle suspension to create a discontinuous gradient. The
gradient samples were centrifuged for 70 minutes at 350,000
xg, 4°C in a Sorvall TST 60.4 swinging bucket rotor using a
Beckman L8-70M Ultracentrifuge. Ten consecutive fractions
of 0.267 mL were collected from top to bottom of the gradient.
The refractive index of each fraction was assessed with an
ABBE-3L refractometer (Fisher Scientific) to calculate the
density of each fraction. All ten fractions were diluted with 1
mL PBS and centrifuged for 70 minutes at 100,000 xg, 4°C in a
S55A2 rotor using a SorvallTM MTX 150 MicroUltracentrifuge. The pellets from the first five sEV fractions
(F1-F5) were pooled and washed in 1 mL PBS and centrifuged
for 70 minutes at 100,000 xg, 4°C in a S55A2 rotor using a
SorvallTM MTX 150 Micro-Ultracentrifuge. The final pellet was
resuspended in 100 μL of PBS and stored at −80°C or utilized
for analysis by NTA, IB, or electroporation as described below.
Electroporation of small extracellular vesicles with siRNAs
For electroporation, DU145 or PC3 sEVs (3 x 109) were mixed
with 4 μg of non-silencing siRNAs (Dharmacon, D-001810-0120), ITGB6 targeting D1 or D13.1 siRNA duplex, or Cy®3 trans
fection control DsiRNAs (Integrated DNA Technologies, 51–0103-08) in ~400 μL of cold electroporation buffer (1.15 mM
K2HPO4 pH 7.2, 25 mM KCl, 21% Optiprep), and transferred
to ice cold electroporation cuvettes (Bio-Rad Gene Pulser®
Cuvette, 165–2088). sEV electroporation was performed using
Bio-Rad MicroPulsarTM Electroporation Apparatus (165–2100)
using a 12 milli-second pulse (6 pulses of 2 milli-second each) at
400 volts. After electroporation, sEVs were incubated on ice for
30 minutes followed by incubation with 100 μg/mL RNase A
(ThermoFisher Scientific, EN0531) at 37°C for 30 minutes. This
was followed by incubation with 1 U/mL of RNase inhibitor
(Invitrogen from ThermoFisher Scientific, AM2694) at 37°C for
30 minutes. The sEVs were washed with 3 mL PBS and centri
fuged using a TLA100.3 rotor in a Beckman OptimaTM TL
Ultracentrifuge at 100,000 xg for 70 minutes, washed with 1
mL PBS and centrifuged using a S55A2 rotor in a SorvallTM
MTX 150 Micro-Ultracentrifuge at 100,000 xg for 70 minutes, or
washed with 30 mL PBS and centrifuged using a Beckman Type
45 Ti rotor in a L7-65 Ultracentrifuge at 100,000 xg for 70 min
utes. After centrifugation, the PBS was removed and the respec
tive sEV pellets electroporated with siRNAs were pooled and
resuspended in 100 μL PBS per sample.
The DU145 and PC3 sEVs electroporated with Cy®3
DsiRNAs were resuspended in 100 μL PBS, plated in black
96-well plates (Thermo Scientific, 137101) and absorbance of
Cy®3 fluorescence was measured using the filter (Ex: 520 nm,
Em: 580–640 nm) on a GloMax® Discover system (Promega
Corporation, USA).
Nanoparticle tracking analysis (NTA)
The size distribution and concentration of sEVs isolated from
the PrCa cells (PC3 and DU145) pre- and post-electroporation
with Cy®3 DsiRNAs, non-silencing siRNAs, or ITGB6-target
ing siRNAs were analyzed using a NanoSight NS300
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instrument (Malvern, UK). Briefly, sEV suspensions were
diluted 1:1000 and/or 1:200 (F1-F5 sEVs) in PBS, and the
analysis was performed using camera settings ranging from
11–13 to visualize the sEV particles. Using the script SOP
standard measurement, video files of 30-second duration
(repeated three times) were captured at a frame rate of 25
frames per second of particles moving under Brownian motion
at a temperature ranging from 22–25°C. The analyses of the
videos were performed at a detection threshold of 5 using NTA
software version 3.1 (build 3.1.54).

Immunofluorescence and confocal microscopy
PC3 and DU145 cells (104) were cultured on fibronectincoated (10 μg/mL) glass coverslips (Fisher Scientific, 12–545100) in 12-well cell culture dishes for 48 hours and incubated
with DU145- or PC3-derived sEVs electroporated with Cy®3
DsiRNA or PBS for 18 hours. Subsequently, cells were washed
with PBS (2 x 5 minutes) at room temperature, fixed with 4%
paraformaldehyde (PFA) for 15 minutes at room temperature,
and washed with PBS (5 minutes x 3 washes) at room tem
perature. Cells were quenched with 50 mM ammonium chlor
ide for 15 minutes at room temperature and washed with PBS
(2 x 5 minutes) at room temperature. Cells were then permea
bilized with 0.25% Triton-X 100 for 10 minutes at room
temperature, washed with PBS (3 x 5 minutes) at room tem
perature, and blocked with 5% bovine serum albumin in PBS
with 0.1% Tween 20 (PBST) for one hour at room tempera
ture. Cells were then incubated with Fluorescein isothiocya
nate labeled-phalloidin (5 μg/mL, Sigma-Aldrich, P5282) at
room temperature for 1 hour, and washed with PBST (3 x
5 minutes) at room temperature. Glass cover slips were then
mounted on VWR vistavisionTM microscope glass slides
(VWR International, 16004–422) using ProLong™ diamond
antifade mountant with DAPI (Invitrogen, P36966). The slides
were analyzed and images were captured using a Nikon A1R
confocal microscope. To evaluate internalization of Cy®3
DsiRNA electroporated sEVs into PC3 and DU145 cells, Zstack image analysis was performed using NIS Elements
Viewer (version 4.11.0) imaging software. The number of
PC3 cells counted was 198 and of DU145 cells was 102.

Inhibition of αVβ6 integrin expression using small
extracellular vesicles electroporated with siRNAs
PC3 cells (2.5 x 105) were plated in a 6-well cell culture dish
using 2 mL of complete media as mentioned above and kept in
a 37°C cell culture incubator. The following day, PC3 cells were
washed with PBS, supplemented with 1 mL of serum-free
media, and treated with iodixanol density gradient purified
DU145 sEVs electroporated without siRNAs (+), DU145
sEVs electroporated with non-silencing siRNAs (+siNS
sEVs), or ITGB6-targeting siRNAs (+siITGB6 sEVs) and incu
bated overnight at 37°C. The following day, PC3 cells were
treated with a second round of electroporated DU145 sEVs as
mentioned above, and incubated overnight at 37°C. The fol
lowing day, PC3 cells treated with the respective sEVs were

washed with PBS, and incubated with 2 mL of complete media
at 37°C. After 7.5 hours, PC3 cells were washed with PBS
followed by cell lysis.
Cell adhesion assay
For cell adhesion assays, 96-well flat bottom adhesion assay
plates (Linbro®/Titertek®, 76–232-05) were coated with
150 μL or 200 μL of 1% BSA in PBS or fibronectin (10 μg/
ml in PBS) or recombinant human LAP-TGFβ1 (10 μg/ml in
PBS, R&D, 246-LP) overnight at 4°C. On the day of the
assay, the coated wells were blocked with 1% BSA in PBS
for 1 hour at room temperature followed by washing with
PBS three times. PC3 cells treated with DU145 sEVs electro
porated with non-silencing siRNAs (+siNS sEVs) or ITGB6targeting siRNAs (+siITGB6 sEVs) were washed with PBS,
detached using 0.05% trypsin-EDTA (Corning, 25–052-CI)
and rinsed with 1 mg/mL soybean trypsin inhibitor (Roche,
10109886001). Cells were spun down, re-suspended in
serum-free media, counted by hemocytometer, plated (2.5 x
104/ 200 μL , 3 replicates) on coated wells and allowed to
settle at 37°C. After 2.5 hours, media were gently aspirated
from wells and cells were washed with PBS (three washes) to
remove the non-adhered cells. For fixing, adhered PC3 cells
were incubated with 200 μL of 3% PFA in each well for
30 minutes at room temperature. After fixation, cells were
washed with PBS (three washes) and stained with crystal
violet (0.5% in water) for 3 hours or overnight at room
temperature. The excess crystal violet was gently washed
with tap water and wells were air-dried. The optical density
(O.D.) of stained PC3 cells were measured at 562 nm in a
spectrophotometer (ThermoScientific Multiskan Spectrum)
using ScanIt software 2.4.4.
Transwell migration assay
For Transwell migration assays, the upper and bottom mem
branes of Transwell inserts (12 μm pore size, Millicell,
PIXP01250) were coated the day before the assay, with 1%
BSA, 10 μg/mL of Fibronectin, or ~7 μg/mL of recombinant
human LAP-TGFβ1 (R&D systems, 246-LP), overnight at 4°C.
The following day, inserts were washed once with PBS,
blocked with 1% BSA for 30 minutes at room temperature,
followed by two PBS washes. PC3 parental cells, PC3 cells
treated with DU145 sEVs electroporated without siRNAs (+),
DU145 sEVs electroporated with NS siRNAs (+siNS sEVs), or
ITGB6-targeting siRNAs (+siITGB6 sEVs) were trypsinized,
neutralized with soybean trypsin inhibitor (1 mg/mL), counted
using a hemocytometer, and plated (5 x 104) using 300 μL
serum-free media in Transwell inserts (3 replicates). The bot
tom chamber of Transwell inserts also consisted of 300 μL
serum-free media. Cells were then incubated at 37°C for
6 hours. Media were then removed from top and bottom of
inserts followed by three washes with PBS. Cells on the top
and bottom of the Transwell inserts were fixed using 3% PFA
for 30 minutes at room temperature. PFA was removed from
the top and bottom of inserts by two PBS washes. Cells on the
top and bottom of inserts were stained with crystal violet
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solution (0.5% crystal violet in water) for 30 minutes at room
temperature. Extra crystal violet stain was washed with water
and inserts were dried. Photomicrographs of the top of each
Transwell insert indicating total number of cells [5 different
field of view (FOV), FOV = 0.044 mm diameter] were cap
tured under an inverted microscope (Nikon Eclipse TS100).
Using a cotton-tipped applicator, cells from the top of the
Transwell inserts were removed and images of cells migrated
to the bottom of the Transwell insert (8 different FOV,
FOV = 0.044 mm diameter) were captured under the inverted
microscope. The number of cells in each FOV mentioned
above were counted manually. The mean of percentage of
migrated cells [(cells migrated to bottom/total number of
cells) x 100] in each condition was calculated and plotted as
a bar graph.
Statistical analyses
ITGB6 Log2 FPKM expression values from RNA-sequencing of
mCRPrCa cases classified as AR- and AR+ were compared
using the two-tail Mann-Whitney non-parametric test. The
αVβ6 integrin IHC scores in LuCaPs grouped as AR- and AR
+ were converted to Log2(1+ IHC score) and compared using
the two-tail Mann-Whitney non-parametric test. The
GraphPad Prism was used to generate bar graphs.
Data for ITGB6 and AR transcript levels in mCRPrCa cases
were downloaded from the PCTA and the association between
ITGB6 and AR expression was tested using the Spearman
correlation test to generate rho and P-value using the corr.
test R function. ggplot2 was used to generate scatter plots
with linear regression lines.
The two-group t-test with Welch’s correction was used
to compare the mean of adhered PC3 cells between groups.
ANOVA with post-hoc Holm-Sidak’s multiple comparison
test or the Kruskal-Wallis test with post-hoc Dunn’s multi
ple comparisons test was used to compare the number of
cells per FOV that adhered to Transwell inserts between
groups. ANOVA with post-hoc Holm-Sidak’s multiple
comparison test was used to compare the mean of %
migrated cells between groups on BSA and FN. The
Kruskal-Wallis test with post-hoc Dunn’s multiple compar
isons test was used to compare the mean of % migrated
cells between groups on LAP-TGFβ1. GraphPad Prism was
used to generate bar graphs.
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